JP2007505923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505923A5 JP2007505923A5 JP2006527060A JP2006527060A JP2007505923A5 JP 2007505923 A5 JP2007505923 A5 JP 2007505923A5 JP 2006527060 A JP2006527060 A JP 2006527060A JP 2006527060 A JP2006527060 A JP 2006527060A JP 2007505923 A5 JP2007505923 A5 JP 2007505923A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- immunogenic composition
- hiv
- dna
- dna immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50319703P | 2003-09-16 | 2003-09-16 | |
| US60/503,197 | 2003-09-16 | ||
| US10/941,164 US7488485B2 (en) | 2003-09-16 | 2004-09-15 | DNA vaccine compositions and methods of use |
| US10/941,164 | 2004-09-15 | ||
| PCT/US2004/030512 WO2005027844A2 (en) | 2003-09-16 | 2004-09-16 | Dna vaccine compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505923A JP2007505923A (ja) | 2007-03-15 |
| JP2007505923A5 true JP2007505923A5 (enExample) | 2011-01-20 |
| JP4989224B2 JP4989224B2 (ja) | 2012-08-01 |
Family
ID=34381064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527060A Expired - Fee Related JP4989224B2 (ja) | 2003-09-16 | 2004-09-16 | Ｄｎａワクチン組成物およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7488485B2 (enExample) |
| EP (1) | EP1667523B1 (enExample) |
| JP (1) | JP4989224B2 (enExample) |
| AU (1) | AU2004273965B2 (enExample) |
| BR (1) | BRPI0414442A (enExample) |
| CA (1) | CA2538840C (enExample) |
| DK (1) | DK1667523T3 (enExample) |
| ES (1) | ES2399875T3 (enExample) |
| IL (1) | IL174325A (enExample) |
| NZ (1) | NZ545954A (enExample) |
| PL (1) | PL1667523T3 (enExample) |
| PT (1) | PT1667523E (enExample) |
| WO (1) | WO2005027844A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488485B2 (en) * | 2003-09-16 | 2009-02-10 | University Of Kansas Medical Center | DNA vaccine compositions and methods of use |
| US8765140B2 (en) * | 2003-09-16 | 2014-07-01 | University Of Kansas Medical Center | DNA vaccine compositions with HIV/SIV gene modifications |
| PT1880008E (pt) * | 2005-05-03 | 2015-08-27 | Inserm Inst Nat De La Santé Et De La Rech Médicale | Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada |
| US7585675B2 (en) * | 2005-11-15 | 2009-09-08 | University Of Kansas Medical Center | Inhibition of HIV and SHIV replication with antisense interleukin-4 |
| FR2979919B1 (fr) * | 2011-09-12 | 2015-12-11 | Centre Nat Rech Scient | Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1 |
| WO2013126469A1 (en) * | 2012-02-21 | 2013-08-29 | Immunogenetix Therapeutics, Inc. | Chimeric dna vaccine compositions and methods of use |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| KR20230131481A (ko) | 2021-01-14 | 2023-09-13 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신 및 이의 사용 방법 |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| US7488485B2 (en) * | 2003-09-16 | 2009-02-10 | University Of Kansas Medical Center | DNA vaccine compositions and methods of use |
| US7122180B2 (en) * | 2000-10-23 | 2006-10-17 | Children's Medical Center Corporation | DNA vectors containing mutated HIV proviruses |
-
2004
- 2004-09-15 US US10/941,164 patent/US7488485B2/en not_active Expired - Fee Related
- 2004-09-16 PT PT4784389T patent/PT1667523E/pt unknown
- 2004-09-16 JP JP2006527060A patent/JP4989224B2/ja not_active Expired - Fee Related
- 2004-09-16 WO PCT/US2004/030512 patent/WO2005027844A2/en not_active Ceased
- 2004-09-16 ES ES04784389T patent/ES2399875T3/es not_active Expired - Lifetime
- 2004-09-16 EP EP04784389A patent/EP1667523B1/en not_active Expired - Lifetime
- 2004-09-16 CA CA2538840A patent/CA2538840C/en not_active Expired - Fee Related
- 2004-09-16 DK DK04784389.1T patent/DK1667523T3/da active
- 2004-09-16 NZ NZ545954A patent/NZ545954A/en not_active IP Right Cessation
- 2004-09-16 AU AU2004273965A patent/AU2004273965B2/en not_active Ceased
- 2004-09-16 PL PL04784389T patent/PL1667523T3/pl unknown
- 2004-09-16 BR BRPI0414442-2A patent/BRPI0414442A/pt active Search and Examination
-
2006
- 2006-03-15 IL IL174325A patent/IL174325A/en not_active IP Right Cessation
-
2009
- 2009-02-09 US US12/368,151 patent/US8003113B2/en not_active Expired - Fee Related
-
2011
- 2011-07-18 US US13/185,164 patent/US8916174B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen et al. | Human immunodeficiency virus vpr product is a virion-associated regulatory protein | |
| Desai et al. | Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences. | |
| JP2010535495A5 (enExample) | ||
| JP2007505923A5 (enExample) | ||
| Abimiku et al. | Subgroup G HIV type 1 isolates from Nigeria | |
| JP2006523224A5 (enExample) | ||
| Haggerty et al. | Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals | |
| Syu et al. | Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity | |
| Yokoyama et al. | Molecular evolution of the human immunodeficiency and related viruses. | |
| De Goede et al. | Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection | |
| ES2683820T3 (es) | Uso de proteínas GAG no de subtipo B para encapsidación lentiviral | |
| JP2004509601A5 (enExample) | ||
| EP2128256A3 (en) | Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes | |
| US5876724A (en) | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein | |
| AU2004273965B2 (en) | DNA vaccine compositions and methods of use | |
| US8765140B2 (en) | DNA vaccine compositions with HIV/SIV gene modifications | |
| Barnett et al. | Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2 | |
| Spire et al. | The env gene variability is not directly related to the high cytopathogenicity of an HIV1 variant | |
| Yokoyama et al. | Molecular phylogeny of the human immunodeficiency and related retroviruses | |
| JP2007515386A5 (enExample) | ||
| Sakai et al. | Compatibility of Tat and Rev transactivators in the primate lentiviruses | |
| Hayami et al. | Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use | |
| Huffman | Investigation of the antiviral effectiveness and Rev inducibility of an antiviral construct expressing HIV-1 protease (Immune deficiency) | |
| Novelli et al. | Construction and characterization of a full-length HIV-192UG001 subtype D infectious molecular clone | |
| CA2325345A1 (en) | Medicaments for inducing cytotoxic t-cells |